next generation glp 1 drugs Pharma Giants Bet on Next-Generation GLP-1 Treatments to Sustain Growth What to Make of the
Description
Wegovys Low Barrier: Wegovy offers an even lower entry point, with its $199 introductory offer and $349 ongoing price
Long-term metabolic benefits that persist Not all benefits disappear with the compound
Empagliflozin Decreases Myocardial Cytoplasmic Na+ through Inhibition of the Cardiac Na+/H+ Exchanger in Rats and Rabbits
PMID: 38639975.
Continued surges in GLP-1 agonist prescriptions are expected, so clinicians that provide sedation/anaesthesia services must understand and account for the unique anaesthetic risks for these patients
Some startups, including Noom, began offering micro-dosed or reformulated compounds to navigate legal gray zones
